73909-16-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-3-methoxytoluene is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and improving the efficacy of existing ones.
Used in Agrochemical Industry:
4-chloro-3-methoxytoluene is utilized as an intermediate in the production of agrochemicals, aiding in the development of effective pesticides and other agricultural products to enhance crop protection and yield.
Used in Dye and Pigment Production:
4-Chloro-3-methoxytoluene is used as a precursor in the synthesis of dyes and pigments, enabling the creation of a wide range of colors for various applications, including textiles, plastics, and printing inks.
Used in Fragrance Industry:
Due to its mild and pleasant odor, 4-Chloro-3-methoxytoluene is used as a component in the formulation of fragrances, adding to the complexity and appeal of scented products in the perfumery, cosmetics, and personal care industries.
It is important to handle 4-chloro-3-methoxytoluene with care, as exposure to large quantities can cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C8H9ClO/c1-6-3-4-7(9)8(5-6)10-2/h3-5H,1-2H3

Upstream product

• 93-51-6 2-Methoxy-4-methylphenol 
• 615-74-7 2-chloro-5-methylphenol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 75-03-6 ethyl iodide 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 765302-70-3 (4-chloro-3-hydroxy-phenyl)-acetic acid ethyl ester 
• 96495-22-6 2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-28-2 1-chloro-2-methoxy-4-(2-nitrovinyl)benzene 
• 144181-29-3 N-propionyl-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-30-6 N-(phenylacetyl)-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-31-7 N-<(3-methoxyphenyl)acetyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-32-8 N-<(4-methoxyphenyl)acetyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 144181-33-9 N-<3-(4-methoxyphenyl)propionyl>-2-(4-chloro-3-methoxyphenyl)ethylamine 
• 103347-14-4 4-(bromomethyl)-1-chloro-2-methoxybenzene 
• 103039-12-9 2-methyl-4-methoxy-5-chloracetophenone 
• 13726-21-1 2-(4-chloro-3-methoxyphenyl)acetonitrile 
• 936727-47-8 2-(3-(benzyloxy)-4-chlorophenyl)acetonitrile 
• 936727-34-3 (4-chloro-3-hydroxy-phenyl)acetonitrile 
• 169045-07-2 2-{[4-chloro-3-(methyloxy)phenyl]methyl}-1H-isoindole-1,3(2H)-dione 

Relevant academic research and scientific papers

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen

SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES

The present invention relates to novel 2-primary amino-4-secondary amino-quinoline derivatives, their manufacture, pharmaceutical compositions comprising them and their use as medicaments. The active compounds of the present invention can be useful as a medicament in the treatment and/or the decreasing and/or the prevention of fibrosis and/or fibrosis related diseases, or for use as a medicament in the treatment and/or the decreasing and/or the prevention of the autophagy and/or autophagy related diseases and for the inhibition of the autophagy flux, or for use in the inhibition of cathepsins B (CTSB), L (CTSL) and/or D (CTSD) and/or cathepsins B (CTSB), L (CTSL) and/or D (CTSD) related diseases; with the proviso that said compounds are not to be used for the treatment of any forms of cancers.

Design, synthesis, in vitro potent antiproliferative activity, and kinase inhibitory effects of new triarylpyrazole derivatives possessing different heterocycle terminal moieties

A new series of triarylpyrazole derivatives having different heterocycle terminal groups have been designed and synthesised. Compounds 1h–j and 1l exhibited the highest mean percentage inhibition against the 58 cancer cell lines at a concentration of 10 μ

Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents

A novel series of substituted pyrimidine compounds bearing N-phenylpyrazole and terminating with aryl and cyclic sulfonamido moiety were designed, synthesized, and evaluated in vitro as antiproliferative agents against a panel of 53 cell lines of differen

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2

A series of 3,4-diarylpyrazole-1-carboxamide derivatives was designed and synthesized. A selected group of the target compounds was tested for in vitro antiproliferative activities over a panel of 60 cancer cell lines at the National Cancer Institute (NCI, Bethesda, MD, USA) at a single-dose concentration of 10 μm, and the four most active compounds 9a, 9l, 9n, and 10o were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. In addition, a selected group of target compounds were tested for inhibitory effect over cyclooxygenase isozymes. Compounds 9a, 9l, 9n, and 10o were also tested for MEK and ERK kinase inhibitory activity using Western blot assay. Compound 10o was selective toward melanoma cell line subpanel, and its antiproliferative activity may be attributed to selective cyclooxygenase-2 inhibition and ERK pathway inhibition.

New triarylpyrazoles as broad-spectrum anticancer agents: Design, synthesis, and biological evaluation

A new series of diarylureas and diarylamides possessing 1,3,4-triarylpyrazole scaffold was designed and synthesized. Their in vitro antiproliferative activities against NCI-60 cell line panel were tested. Most of the compounds showed strong and broad-spec

Preparation of (2E,4E)-2-(2-benzyloxyethyl)-5-(3-methoxy-4-chlorophenyl) penta-2,4-dienal as a key intermediate in the synthesis of strobilurin B

(2E,4E)-2-(2-Benzyloxyethyl)-5-(4-chloro-3-methoxyphenyl)penta-2,4-dienal was obtained by the condensation of 4-benzyloxybutanal N-tert-butylimine with 4-chloro-3-methoxycinnamic aldehyde with ≥98% configurational purity and 40% yield. When 4-benzyloxy-2-triethylsilylbutanal imine was used, a 7: 3 mixture of the target (2E,4E)-dienal with its (2Z,4E)-isomer was obtained in 60% yield; the latter quantitatively isomerized to the thermodynamically preferable target (2E,4E)-dienal.

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.